ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.929,66
0,15%
S&P 500
5.996,66
1,00%
Dow Jones
43.487,83
0,78%
Euro vs US Dollar
1,03404
0,62%
Bitcoin
107.608,27
4,36%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. SciSparc Ltd (SPRC)

  7. SciSparc Ltd (SPRC) News

SPRC

SciSparc (SPRC)

SciSparc Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SPRC
DatumZeitQuelleÜberschriftSymbolFirma
15/01/202522h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
15/01/202513h34GlobeNewswire Inc.SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementNASDAQ:SPRCSciSparc Ltd
13/01/202514h41GlobeNewswire Inc.SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric VehiclesNASDAQ:SPRCSciSparc Ltd
07/01/202513h25GlobeNewswire Inc.SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive ResultsNASDAQ:SPRCSciSparc Ltd
07/01/202512h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
06/01/202513h50GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentNASDAQ:SPRCSciSparc Ltd
31/12/202422h16Edgar (US Regulatory)Form F-4/A - Registration of securities, foreign private issuers, business combinations: [Amend]NASDAQ:SPRCSciSparc Ltd
31/12/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
31/12/202415h24GlobeNewswire Inc.SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
26/12/202422h06Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SPRCSciSparc Ltd
26/12/202422h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
26/12/202412h46GlobeNewswire Inc.SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct ImportationNASDAQ:SPRCSciSparc Ltd
17/12/202413h53Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
16/12/202413h40GlobeNewswire Inc.SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded CompanyNASDAQ:SPRCSciSparc Ltd
29/11/202414h56Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SPRCSciSparc Ltd
29/11/202414h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
27/11/202422h53Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SPRCSciSparc Ltd
27/11/202422h50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
04/11/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
23/10/202414h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
22/10/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
30/09/202415h25GlobeNewswire Inc.SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentNASDAQ:SPRCSciSparc Ltd
27/09/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
26/09/202415h21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
26/09/202415h05GlobeNewswire Inc.SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareXNASDAQ:SPRCSciSparc Ltd
23/09/202415h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
23/09/202414h17GlobeNewswire Inc.SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome TreatmentNASDAQ:SPRCSciSparc Ltd
18/09/202422h09GlobeNewswire Inc.SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentNASDAQ:SPRCSciSparc Ltd
16/09/202422h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
16/09/202422h06GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination TherapyNASDAQ:SPRCSciSparc Ltd
 Showing the most relevant articles for your search:NASDAQ:SPRC

Kürzlich von Ihnen besucht

TG
BBCK
Invesco Global Buyback A...
BOV
COGN3
COGNA ON
DGFX
OXTUSDT
Orchid
LSE
HS06
Barclays 27
AMEX
RSP
Invesco S&P 500 Equal We...
COIN
SDLEUR
Saddle DAO
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten